416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors

• Vivek Subbiah,
• Ravi Murthy,
• Alexander Guminski,
• Ding Wang,
• Vivek Bhadri,
• Nam Bui,
• Jose Mejia Oneto,
• Kamalesh Sankhala,
• M Wayne Saville,
• Sangeetha Srinivasan,
• Robert Steffner,
• Nathan Yee

Affiliations

Vivek Subbiah

MD Anderson Cancer Center, Houston, TX, USA

Ravi Murthy

MD Anderson Cancer Center, Houston, TX, USA

Alexander Guminski

3Royal North Shore Hospital, St Leonards, Australia

Ding Wang

8Henry Ford Hospital, Detroit, MI, USA

Vivek Bhadri

1Chris O’Brien Lifehouse, Camperdown, Australia

Nam Bui

2Stanford Cancer Institute, Palo Alto, CA, USA

Jose Mejia Oneto

4Shasqi, Inc., San Francisco, CA, USA

Kamalesh Sankhala

6Cedars-Sinai Angeles Clinic, Santa Monica, CA, USA

M Wayne Saville

4Shasqi, Inc., San Francisco, CA, USA

Sangeetha Srinivasan

4Shasqi, Inc., San Francisco, CA, USA

Robert Steffner

7Stanford Medicine, Redwood City, CA, USA

Nathan Yee

4Shasqi, Inc., San Francisco, CA, USA